Zaltenibart

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

The $340 million upfront payment strengthens Omeros’ cash position, with Novo targeting Phase 3 PNH trials after closing.